Half-a-Billion Novel Polio Vaccines Administered
To better address the evolving risk of type 2 circulating vaccine-derived poliovirus (cVDPV2), the Global Polio Eradication Initiative (GPEI) with countries are deploying an innovative novel oral polio vaccine type 2 (nOPV2) to reduce the spreading of poliovirus.
The GPEI recently reported about 525 million doses of the nOPV2 polio vaccine had been administered across 25 countries under its WHO Emergency Use Listing.
As of November 30, 2022, an additional 15 countries have met the requirements for nOPV2 use in the event of an outbreak.
The new vaccine is a modified version of the type 2 monovalent Oral Polio Vaccine, which clinical trials have shown provides comparable protection against poliovirus while being more genetically stable and less likely to be associated with the emergence of cVDPV2.
This means that nOPV2 has the potential to be a significant tool to help stop polio outbreaks, says the GPEI.
In 2022, poliovirus was confirmed in non-endemic countries in Africa, Asia, Europe, India, Israel, the United Kingdom, and the state of New York.
To notify people of their potential polio health risks, the U.S. CDC issued an updated global Alert - Level 2, Practice Enhanced Precautions on November 30, 2022.
As of December 5, 2022, the nOPV2 vaccine is not approved by the U.S. FDA.
The IPV vaccine has been offered in the U.S. since 2022.
Additional polio outbreak information is posted at PrecisionVaccinations.com/Polio.